RECENT FUNDING
  1. Recent Funding
  2. Investors
  3. Mission BioCapital
M

Mission BioCapital portfolio

Mission BioCapital has 13 portfolio companies on record at Recent Funding, with 5 investments in the last 12 months.

Type: Venture capital.
Portfolio on Recent Funding: 13.
Deals, last 12 months: 5.
Rounds led: 2 of 14.
Capital in their rounds: $1.07B.
Latest deal: Oyster Therapeutics · Nov 10, 2026.
About this page

It is a venture capital firm based in San Francisco, US, founded in 2009. It led 2 of the 14 rounds it joined. Its most recent investment on record is Oyster Therapeutics's $60M Series A round in November 2026, alongside Global Brain Corporation, 4BIO Capital, Eli Lilly and 5 others. By category, its portfolio leans toward Health and bio (12) and Robotics and hardware (1). It has co-invested with Pfizer Venture Investments, Eli Lilly and Taiho Ventures, most often Pfizer Venture Investments (4 rounds).

About Mission BioCapital

Firm type: Venture capital.
Headquarters: San Francisco, US.
Founded: 2009.
Stages: Pre-Seed, Seed, Series A.
Sectors: AgTech, Biotech, Deep Tech, Digital Health, FoodTech, Healthtech, Longevity, Medical Devices, New Materials.
Check size: $500K.
Leads rounds: No.
Portfolio companies: 71.
Exits: 3.
Rounds led: 1.

Funds raised

FundFund #SizeAnnounced
MMission BioCapitalVI$143.8M
Venture Capital Journal

What Mission BioCapital invests in

Mission BioCapital recent investments

How Mission BioCapital invests

StageDealsCapital in rounds
Series A 8 57%$380.15M
Series B+ 4 29%$305M
Seed 1 7%$33M
round 1 7%$350M
YearDealsCapital in rounds
2019 2 14%$57M
2020 1 7%undisclosed
2021 3 21%$216M
2022 2 14%$129M
2023 1 7%$105M
2025 1 7%$41.5M
2026 4 29%$519.65M

Mission BioCapital portfolio companies

CompanyRound with Mission BioCapitalTotal raisedLatest raise
OOyster Therapeutics
Health and bio
Series A · $60M$60MNov 10, 2026
Series A
DDren Bio
Health and bio
round · $350M$415MOct 29, 2026
round
BBreye Therapeutics
Health and bio
Series A · $76.65M · lead$80.77MSep 29, 2026
Series A
CCloverleaf Bio
Health and bio
Seed · $33M$33MSep 8, 2026
Seed
AAI Proteins
Health and bio
Series A · $41.5M · lead$59.7MNov 18, 2025
Series A
MMediar Therapeutics
Health and bio
Series A · $105M$181MJan 7, 2026
Series B+
AArkuda Therapeutics
Health and bio
Series B+ · $64M$108MFeb 10, 2022
Series B+
TTune Therapeutics
Health and bio
Series A · $40M$215MJan 12, 2025
Series B+
AAsher Bio
Health and bio
Series B+ · $108M$218MApr 16, 2024
Series B+
GGlycomine
Health and bio
Series B+ · $68M$195MMay 9, 2025
Series B+
WWildtype
Commerce and retail
Series A · $13M$117MMar 24, 2026
Series B+
ZZag Bio
Health and bio
backerundisclosed—
JJupiter Bioventures
Health and bio
backerundisclosedOct 8, 2025
Series B+

Most frequent co-investors

Similar investors

Investors whose portfolios on Recent Funding center on the same category (Health and bio).

How this is counted

Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.

Venture funds Mission BioCapital raised, from the list of new VC funds compiled by Shai Goldman (Brex). Each size links to the article that states it, or to that list where no article was found. All new funds: new VC funds.

Share is of the 14 rounds on Recent Funding that name Mission BioCapital. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.

Portfolio companies are the companies on Recent Funding with a round that lists Mission BioCapital, which is a subset of its real portfolio. API: /api/v1/investors/mission-biocapital (get a free API key). More: the most active VC firms and new venture capital funds.

Top raises, every week

The week's top funded startups and market insights, in your inbox every Monday.

Unsubscribe anytime · privacy